222 related articles for article (PubMed ID: 22997967)
1. Usefulness of cytokeratin-19, galectin-3, and Hector Battifora mesothelial-1 in the diagnosis of benign and malignant thyroid nodules.
Cui W; Sang W; Zheng S; Ma Y; Liu X; Zhang W
Clin Lab; 2012; 58(7-8):673-80. PubMed ID: 22997967
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules.
Abd-El Raouf SM; Ibrahim TR
Pathol Res Pract; 2014 Dec; 210(12):971-8. PubMed ID: 25041837
[TBL] [Abstract][Full Text] [Related]
3. Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-{gamma}, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma.
Liu YY; Morreau H; Kievit J; Romijn JA; Carrasco N; Smit JW
Eur J Endocrinol; 2008 Mar; 158(3):375-84. PubMed ID: 18299472
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic significance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinoma.
Zhu X; Sun T; Lu H; Zhou X; Lu Y; Cai X; Zhu X
J Clin Pathol; 2010 Sep; 63(9):786-9. PubMed ID: 20644217
[TBL] [Abstract][Full Text] [Related]
5. Expression of cytokeratin 19, HBME-1 and galectin-3 in neoplastic and nonneoplastic thyroid lesions.
Mataraci EA; Ozgüven BY; Kabukçuoglu F
Pol J Pathol; 2012 Mar; 63(1):58-64. PubMed ID: 22535608
[TBL] [Abstract][Full Text] [Related]
6. Expression of Galectin-3 and Galectin-7 in thyroid malignancy as potential diagnostic indicators.
Than TH; Swethadri GK; Wong J; Ahmad T; Jamil D; Maganlal RK; Hamdi MM; Abdullah MS
Singapore Med J; 2008 Apr; 49(4):333-8. PubMed ID: 18418527
[TBL] [Abstract][Full Text] [Related]
7. [Expression of cytokeratin19, galectin-3 and HBME-1 in thyroid lesions and their differential diagnoses].
Teng XD; Wang LJ; Yao HT; Li J; Ding W; Yan LP
Zhonghua Bing Li Xue Za Zhi; 2004 Jun; 33(3):212-6. PubMed ID: 15256110
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy.
de Matos PS; Ferreira AP; de Oliveira Facuri F; Assumpção LV; Metze K; Ward LS
Histopathology; 2005 Oct; 47(4):391-401. PubMed ID: 16178894
[TBL] [Abstract][Full Text] [Related]
9. The use of a combination of Ki-67, Galectin-3, and PTTG can distinguish the benign and malignant thyroid tumor.
Cui W; Lu X; Zheng S; Ma Y; Liu X; Zhang W
Clin Lab; 2012; 58(5-6):419-26. PubMed ID: 22783570
[TBL] [Abstract][Full Text] [Related]
10. [Usefulness of CK19, HBME-1 and galectin-3 expressions in differential diagnosis of thyroid papillary microcarcinoma from benign lesions].
Tong J; Wang Y; Da JP
Zhonghua Zhong Liu Za Zhi; 2011 Aug; 33(8):599-604. PubMed ID: 22325220
[TBL] [Abstract][Full Text] [Related]
11. Galectin-3 is highly expressed in nonencapsulated papillary thyroid carcinoma but weakly expressed in encapsulated type; comparison with Hector Battifora mesothelial cell 1 immunoreactivity.
Torregrossa L; Faviana P; Camacci T; Materazzi G; Berti P; Minuto M; Elisei R; Vitti P; Miccoli P; Basolo F
Hum Pathol; 2007 Oct; 38(10):1482-8. PubMed ID: 17597183
[TBL] [Abstract][Full Text] [Related]
12. Utility of galectin 3 expression in thyroid aspirates as a diagnostic marker in differentiating benign from malignant thyroid neoplasms.
Aron M; Kapila K; Verma K
Indian J Pathol Microbiol; 2006 Jul; 49(3):376-80. PubMed ID: 17001889
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid.
Rossi ED; Raffaelli M; Mule' A; Miraglia A; Lombardi CP; Vecchio FM; Fadda G
Histopathology; 2006 Jun; 48(7):795-800. PubMed ID: 16722927
[TBL] [Abstract][Full Text] [Related]
14. Ultrasound Risk Assessment Combined with Molecular Markers of Galectin-3, c-MET, HBME-1 and CK19 for Diagnosis of Malignant and Benign Thyroid Nodules.
Han RL; Wang J; Zhang FJ; Zhao N; Gao BL
Pathol Oncol Res; 2019 Jul; 25(3):1075-1081. PubMed ID: 30361909
[TBL] [Abstract][Full Text] [Related]
15. [Expression of GADD153 in follicular tumors of thyroid and comparison with CK19, Galectin-3 and HBME-1].
Tang QS; Teng XD; Ding W; Zhou J; Yao HT; Ying LX; Xu LM
Zhonghua Bing Li Xue Za Zhi; 2011 Nov; 40(11):745-8. PubMed ID: 22336157
[TBL] [Abstract][Full Text] [Related]
16. Role of cd56 and e-cadherin expression in the differential diagnosis of papillary thyroid carcinoma and suspected follicular-patterned lesions of the thyroid: the prognostic importance of e-cadherin.
Ceyran AB; Şenol S; Şimşek BÇ; Sağıroğlu J; Aydın A
Int J Clin Exp Pathol; 2015; 8(4):3670-80. PubMed ID: 26097548
[TBL] [Abstract][Full Text] [Related]
17. Universal markers of thyroid malignancies: galectin-3, HBME-1, and cytokeratin-19.
Barut F; Onak Kandemir N; Bektas S; Bahadir B; Keser S; Ozdamar SO
Endocr Pathol; 2010 Jun; 21(2):80-9. PubMed ID: 20198455
[TBL] [Abstract][Full Text] [Related]
18. CXC motif ligand 12 as a novel diagnostic marker for papillary thyroid carcinoma.
Chung SY; Park ES; Park SY; Song JY; Ryu HS
Head Neck; 2014 Jul; 36(7):1005-12. PubMed ID: 23784811
[TBL] [Abstract][Full Text] [Related]
19. HBME-1 and CK19 are highly discriminatory in the cytological diagnosis of papillary thyroid carcinoma.
Nga ME; Lim GS; Soh CH; Kumarasinghe MP
Diagn Cytopathol; 2008 Aug; 36(8):550-6. PubMed ID: 18618720
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic value of HBME-1, CD56, Galectin-3 and Cytokeratin-19 in papillary thyroid carcinomas and thyroid tumors of uncertain malignant potential.
Nechifor-Boilă A; Cătană R; Loghin A; Radu TG; Borda A
Rom J Morphol Embryol; 2014; 55(1):49-56. PubMed ID: 24715165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]